EMA Authorised: Ilaris (Canakinumab) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Ilaris (canakinumab) for use in Cryopyrin-Associated Periodic Syndromes, juvenile idiopathic arthritis, and gout.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryopyrin-associated Periodic Syndromes
• Gout
• Juvenile Idiopathic Arthritis

Drugs mentioned

• ILARIS (canakinumab)

Snippet

Status: Authorised. Therapeutic area: Cryopyrin-Associated Periodic Syndromes;Arthritis, Juvenile Rheumatoid;Arthritis, Gouty. MAH: Novartis Europharm Limited. Decision date: 04/02/2025